Analytical validation of the Oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor-positive breast cancer.

@article{Cronin2007AnalyticalVO,
  title={Analytical validation of the Oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor-positive breast cancer.},
  author={Maureen T. Cronin and Chithra Sangli and Mei-lan Liu and Mylan Pho and Debjani Dutta and Anhthu N Nguyen and Jennie Jeong and Jenny Wu and Kim Clark Langone and Drew Watson},
  journal={Clinical chemistry},
  year={2007},
  volume={53 6},
  pages={1084-91}
}
BACKGROUND Oncotype DX is a clinically validated, high-complexity, multianalyte reverse transcription-PCR genomic test that predicts the likelihood of breast cancer recurrence in early-stage, node-negative, estrogen receptor-positive breast cancer. The Recurrence Score (RS) provides a more accurate, reproducible measure of breast cancer aggressiveness and therapeutic responsiveness than standard measures. Individualized patient management requires strict performance criteria for clinical… CONTINUE READING
124 Citations
34 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 124 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 34 references

Development and validation of therapeutically relevant multi-gene biomarker classifiers

  • R. Simon
  • J Natl Cancer Inst
  • 2005

Gene expression profiling of breast cancer: a new tumor marker

  • LJ van’t Veer, S Paik, DF. Hayes
  • J Clin Oncol
  • 2005

Similar Papers

Loading similar papers…